Our latest articles
Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.
In the Kras plus checkpoint inhibitor race it looks like advantage Mirati, for now.
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.